A5021067684- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Genomics and Chromatin Dynamics
- Virus-based gene therapy research
- Immune Cell Function and Interaction
Imperial College London
2022
University of Manchester
2020
Cancer Research UK Manchester Institute
2020
Abstract Mutations in the estrogen receptor (ESR1) gene are common ER-positive breast cancer patients who progress on endocrine therapies. Most mutations localise to just three residues at, or near, C-terminal helix 12 of hormone binding domain, at leucine-536, tyrosine-537 and aspartate-538. To investigate these mutations, we have used CRISPR-Cas9 mediated genome engineering generate a comprehensive set isogenic mutant cell lines. Our results confirm that L536R, Y537C, Y537N, Y537S D538G...